Mezzion Pharma Co., Ltd. Logo

Mezzion Pharma Co., Ltd.

Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.

140410 | KO

Overview

Corporate Details

ISIN(s):
KR7140410002
LEI:
Country:
South Korea
Address:
서울특별시 강남구 삼성로 570 석천빌딩 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics, with a particular emphasis on rare diseases. The company's primary efforts are centered on its drug candidate, udenafil, for various medical conditions. A key initiative is the development of udenafil for adolescents living with Fontan circulation, a rare congenital heart condition, supported by a large-scale Phase 3 clinical trial (FUEL-2). Mezzion's pipeline also includes potential treatments for pulmonary arterial hypertension (PAH), portal hypertension, and erectile dysfunction. The company's business model involves developing pharmaceutical products and out-licensing them for international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.9 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 101.3 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 107.8 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 67.0 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 94.9 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 972.3 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.7 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.5 MB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 143.7 KB

Automate Your Workflow. Get a real-time feed of all Mezzion Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mezzion Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mezzion Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PURPLE BIOTECH LTD. Logo
Develops first-in-class therapies targeting tumor immune evasion and drug resistance in cancer.
United States of America
PPBT
Pyxis Oncology, Inc. Logo
Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.
United States of America
PYXS
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland
CRM
Q32 Bio Inc. Logo
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
United States of America
QTTB
Quantum Biopharma Ltd. Logo
Develops therapies for brain disorders and a functional beverage for post-alcohol wellness.
United States of America
QNTM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France
ALQGC
QuidelOrtho Corp Logo
Manufactures in-vitro diagnostic tests for at-home, point-of-care, and clinical lab settings.
United States of America
QDEL
Quince Therapeutics, Inc. Logo
Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.
United States of America
QNCX
Quoin Pharmaceuticals, Ltd. Logo
Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.
United States of America
QNRX
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea
348080

Talk to a Data Expert

Have a question? We'll get back to you promptly.